超声引导的个性化机械通气治疗急性呼吸窘迫综合征患者(PEGASUS):一项国际随机临床试验的研究方案
PEGASUS 是一项由研究者发起的国际随机临床试验,计划纳入 538 例接受有创机械通气的中重度急性呼吸窘迫综合征(ARDS)成人 ICU 患者。患者先接受肺超声检查将肺形态分为「局灶型」或「非局灶型」,随后在 ARDS 诊断后 12 小时内随机接受标准治疗或按形态亚表型调整的个性化通气(非局灶型用较高呼气末正压和肺复张手法,局灶型用较低呼气末正压和俯卧位通气)。主要终点为第 90 天全因死亡率。
要点
- PEGASUS 计划纳入 538 例有创通气的中重度 ARDS 成人 ICU 患者。
- 肺超声用于区分「局灶型」与「非局灶型」肺形态,并据此调整通气策略。
- 主要终点为第 90 天全因死亡率;先进行 80 例患者试点阶段评估。
核心结论
- PEGASUS 是首个在有创通气的中重度 ARDS 患者中比较肺超声引导的个性化机械通气与常规通气的随机对照试验。
- 若该研究显示肺超声引导的个性化通气能改善 ARDS 患者结局,则有可能将现有「一刀切」通气策略转向更个体化的方法。
研究设计与样本
- 研究者发起的国际随机临床试验,计划纳入 538 例接受有创通气的中重度 ARDS 成人 ICU 患者。
- 患者先接受肺超声检查,将肺形态分为「局灶型」或「非局灶型」。
- 在 ARDS 诊断后 12 小时内随机分为标准治疗组或个性化通气组,后者按形态亚表型调整通气策略。
- 个性化通气策略为:非局灶型 ARDS 采用较高呼气末正压和肺复张手法,局灶型 ARDS 采用较低呼气末正压和俯卧位通气。
- 试点阶段纳入 80 例患者后,评估肺超声图像的正确判读及在机械通气安全范围内正确实施干预的情况。
主要发现
- 主要终点为第 90 天全因死亡率。
- 次要结局包括第 28 天死亡率、第 28 天无呼吸机天数、ICU 住院时长、ICU 死亡率、住院时长、住院死亡率及并发症数量(呼吸机相关性肺炎、气胸和需要补救治疗)。
- ARDS 是低氧性呼吸衰竭的常见原因,死亡率约为 30%。
关键数值与推荐
- 计划纳入 538 例接受有创通气的中重度 ARDS 成人 ICU 患者。
- ARDS 诊断后 12 小时内完成随机分组。
- 试点阶段为 80 例患者。
- 主要终点为第 90 天全因死亡率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a frequent cause of hypoxemic respiratory failure with a mortality rate of approximately 30%. Identifying ARDS subphenotypes based on "focal" or "non-focal" lung morphology has the potential to better target mechanical ventilation strategies of individual patients. However, classifying morphology through chest radiography or computed tomography is either inaccurate or impractical. Lung ultrasound (LUS) is a non-invasive bedside tool that can accurately distinguish "focal" from "non-focal" lung morphology. We hypothesize that LUS-guided personalized mechanical ventilation in ARDS patients leads to a reduction in 90-day mortality compared to conventional mechanical ventilation. METHODS: The Personalized Mechanical Ventilation Guided by UltraSound in Patients with Acute Respiratory Distress Syndrome (PEGASUS) study is an investigator-initiated, international, randomized clinical trial (RCT) that plans to enroll 538 invasively ventilated adult intensive care unit (ICU) patients with moderate to severe ARDS. Eligible patients will receive a LUS exam to classify lung morphology as "focal" or "non-focal". Thereafter, patients will be randomized within 12 h after ARDS diagnosis to receive standard care or personalized ventilation where the ventilation strategy is adjusted to the morphology subphenotype, i.e., higher positive end-expiratory pressure (PEEP) and recruitment maneuvers for "non-focal" ARDS and lower PEEP and prone positioning for "focal" ARDS. The primary endpoint is all-cause mortality at day 90. Secondary outcomes are mortality at day 28, ventilator-free days at day 28, ICU length of stay, ICU mortality, hospital length of stay, hospital mortality, and number of complications (ventilator-associated pneumonia, pneumothorax, and need for rescue therapy). After a pilot phase of 80 patients, the correct interpretation of LUS images and correct application of the intervention within the safe limits of mechanical ventilation will be evaluated. DISCUSSION: PEGASUS is the first RCT that compares LUS-guided personalized mechanical ventilation with conventional ventilation in invasively ventilated patients with moderate and severe ARDS. If this study demonstrates that personalized ventilation guided by LUS can improve the outcomes of ARDS patients, it has the potential to shift the existing one-size-fits-all ventilation strategy towards a more individualized approach. TRIAL REGISTRATION: The PEGASUS trial was registered before the inclusion of the first patient, https://clinicaltrials.gov/ (ID: NCT05492344).
引用
- Sinnige JS, Smit MR, Ghose A, et al. Personalized mechanical ventilation guided by ultrasound in patients with acute respiratory distress syndrome (PEGASUS): study protocol for an international randomized clinical trial. Trials. 2024. PMID: 38715118. doi:10.1186/s13063-024-08140-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。